Jonathan Samuel Berek, MD
Gynecologic Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Berek’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G39480 · Current
Licensed to practise in California · since 1979 · expires 2027-04-30 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Gynecologic Oncology
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 11 Part D prescriptions in 2014. Too few prescriptions to judge: with under about 50 a year, a handful of patients can swing this share.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2014 | 11 | None | 0% (0) | None | $1,274 |
| 2013 | 24 | None | 0% (0) | None | $1,462 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$4,040 in 2025
| 2025 | 1 | 2 | $4,040 | $4,040 |
| 2024 | 2 | 3 | $5,490 | $5,555 |
| 2023 | 1 | 4 | $10,930 | $10,930 |
| 2022 | 3 | 6 | $13,485 | $13,485 |
| 2021 | 2 | 2 | $6,200 | $6,200 |
| 2020 | 2 | 3 | $10,550 | $10,550 |
| 2019 | 2 | 3 | $3,125 | $3,125 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $4,040 | 2 payments
|
See all 2 published payments
| Merck Sharp & Dohme | Consulting · 2025-08-20 | None | $1,600 |
| Merck Sharp & Dohme | Consulting · 2025-05-19 | Keytruda | $2,440 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $5,555
| Merck Sharp & Dohme | Lynparza | $5,490 | 2 payments
|
| GlaxoSmithKline | Zejula | $65 | 1 payment
|
2023: $10,930
| Merck Sharp & Dohme | Lynparza | $10,930 | 4 payments
|
2022: $13,485
| Merck Sharp & Dohme | Keytruda | $9,410 | 4 payments
|
| Novocure GmbH | None | $3,520 | 1 payment
|
| AstraZeneca UK | Imfinzi | $555 | 1 payment
|
2021: $6,200
| Novocure GmbH | None | $3,200 | 1 payment
|
| Merck Sharp & Dohme | None | $3,000 | 1 payment
|
2020: $10,550
| Merck Sharp & Dohme | Mk-7339 | $5,750 | 2 payments
|
| Novocure | Oncology | $4,800 | 1 payment
|
2019: $3,125
| Merck Sharp & Dohme | Mk-7339 | $1,625 | 2 payments
|
| Eisai | None | $1,500 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| TESARO, Inc. · A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer · 2019 | Their institution | $318,934 |
| Karyopharm Therapeutics Inc. · Xpovio · 2020 | Their institution | $92,169 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized Double-Blind Trial of Maintenance With Niraparib · 2020 | Their institution | $63,624 |
| TESARO, Inc. · A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens · 2019 | Their institution | $58,891 |
| Karyopharm Therapeutics Inc. · A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/Placebo After Combination Chemotherapy for Patients With Advanced Or Recurrent Endometrial Cancer · 2021 | Their institution | $52,465 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized Double-Blind Trial of Maintenance With Niraparib · 2019 | Their institution | $42,365 |
| Karyopharm Therapeutics Inc. · A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With P53 Wild-Type, Advanced Or Recurrent Endometrial Carcinoma · 2023 | Their institution | $37,500 |
| Karyopharm Therapeutics Inc. · A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/Placebo After Combination Chemotherapy for Patients With Advanced Or Recurrent Endometrial Cancer · 2022 | Their institution | $36,739 |
| ABBVIE INC. · Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab As Maintenance in Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, Or Peritoneal Cancer (Gloriosa) · 2024 | Their institution | $33,000 |
| Karyopharm Therapeutics Inc. · A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/Placebo After Combination Chemotherapy for Patients With Advanced Or Recurrent Endometrial Cancer · 2023 | Their institution | $21,788 |
| Karyopharm Therapeutics Inc. · A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/Placebo After Combination Chemotherapy for Patients With Advanced Or Recurrent Endometrial Cancer · 2024 | Their institution | $14,400 |
| Karyopharm Therapeutics Inc. · A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With P53 Wild-Type, Advanced Or Recurrent Endometrial Carcinoma · 2025 | Their institution | $12,936 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized Double-Blind Trial of Maintenance With Niraparib · 2022 | Their institution | $9,577 |
| ABBVIE INC. · Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab As Maintenance in Platinum-Sensitive Ovarian, Fallopian Tube, Or Peritoneal Cancer (Gloriosa) · 2025 | Their institution | $9,086 |
| Karyopharm Therapeutics Inc. · A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With P53 Wild-Type, Advanced Or Recurrent Endometrial Carcinoma · 2024 | Their institution | $3,467 |
| GlaxoSmithKline, LLC. · A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of · 2022 | Their institution | $2,342 |
| GlaxoSmithKline, LLC. · A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of · 2023 | Their institution | $2,232 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1164447900
- Licence
- CA G39480California G39480: Current · expires 2027-04-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X); Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-13
- NPI last updated
- 2024-04-19
- NPI record certified
- 2024-04-19
This is when the NPI record was last certified, not a medical board exam.